Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says
Executive Summary
Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15
You may also be interested in...
Novartis Gains Hepatitis Market Access Through Idenix Majority Stake
Novartis is adding three novel hepatitis products to its antiviral pipeline through a 51% stake in the privately held biotech company Idenix
Novartis Boxes In Roche, Ups Ownership Stake To “Blocking Minority”
Novartis is upping the pressure on Roche to negotiate a merger agreement - or face the threat of a veto by its Swiss neighbor on any strategic moves it undertakes
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011